EichorEICHOR
Condition: Residual Invasive Breast Cancer Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Residual Invasive Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Neg
Phase 3 · 356 location(s) · Gilead Sciences · NCT05633654A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer
Phase 3 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06830889Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
Phase 3 · 1 location(s) · RenJi Hospital · NCT04254263ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Phase N/A · 57 location(s) · Guardant Health, Inc. · NCT05059444Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
Phase 2 · 1 location(s) · Chinese Academy of Medical Sciences · NCT04437160Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT05196087
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.